The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. Through the IMI2 programme, a €3.3 billion budget for the period 2014-2020 is available.
Find out more:
European Commission Research & Innovation: